TG Therapeutics reports Phase II data for umbralisib in CLL

TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib (TGR-1202) led to nodal reductions in nearly all patients evaluable for response, including three patients with

Read the full 245 word article

User Sign In